Humana is a leading health insurance company that provides a wide range of health and wellness solutions to individuals, families, and employers. The organization offers Medicare Advantage plans, Medicaid services, and individual health insurance policies, focusing on enhancing the health and well-being of its members. Additionally, Humana invests in technology and innovative care management services, aiming to improve healthcare delivery and patient outcomes. The company is dedicated to integrating medical and wellness services to create a comprehensive approach to health management for its customers. Read More
Shares of health insurance company Humana (NYSE:HUM)
jumped 6.4% in the afternoon session after the company provided a positive update on its Medicare star ratings and affirmed its full-year earnings guidance.
On the second day of the U.S. government shutdown, Wall Street remains largely subdued, with indexes showing only slight midday declines after touching fresh record highs at the open.
Stocks with low volatility can be a great foundation for a portfolio, especially for investors looking to reduce risk.
While they don’t often make headlines, these companies provide consistency in an unpredictable market.
Shares of health insurance company Humana (NYSE:HUM)
fell 5.2% in the afternoon session after the company announced it will reduce the reach of its Medicare Advantage plans next year, citing rising costs. The health insurer will decrease its Medicare Advantage presence from 48 states to 46 and will cover 85% of U.S. counties, down from 89% this year. This decision comes as insurers face higher utilization of medical services and claim that government payments have not kept up with increasing costs. The pullback is not unique to Humana, as other major insurers are also retreating from less profitable markets. For instance, CVS Health's Aetna announced a similar reduction in its plan offerings. Despite the smaller footprint for its main Medicare Advantage plans, Humana did note that it expects to lower premiums for about 83% of its stand-alone prescription drug plans in the coming year.
Humana Inc. (NYSE: HUM), a leading health and well-being company, today announced its Medicare Advantage and Medicare Prescription Drug Plan offerings for 2026. During the Medicare Annual Election Period (AEP) Oct. 15-Dec. 7, Medicare beneficiaries may review plan changes for the coming year and select a plan to meet their evolving healthcare needs.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.6% gain.
Humana Inc. (NYSE: HUM), a leading health and well-being company, is taking pickleball on the road to celebrate their ongoing commitment to creating experiences that enable health, enhance activity, and foster connectivity.
Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Humana (HUM) To Contact Him Directly To Discuss Their Options
The Centers for Medicare & Medicaid Services (CMS) is poised to usher in a new era of healthcare administration with the upcoming launch of the Wasteful and Inappropriate Service Reduction (WISeR) Model. This groundbreaking pilot program, set to begin on January 1, 2026, will integrate artificial intelligence (AI) into the prior
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year trend of muted returns for a sector traditionally viewed as defensive and resilient. The underperformance is not merely
The healthcare payer industry is reeling following a challenging second quarter, epitomized by UnitedHealth Group's (NYSE: UNH) significant earnings miss and the deepening shadow of a federal Medicare fraud investigation. These developments are not isolated incidents but rather stark indicators of mounting pressures within the health insurance sector, characterized by
The healthcare sector is currently experiencing a period of profound transformation, marked by a fascinating dichotomy: groundbreaking medical innovations are driving unprecedented growth for some, while intense regulatory scrutiny and escalating costs pose significant challenges for others. This intricate interplay between scientific advancement and a complex operating environment is reshaping
UnitedHealth Group (NYSE: UNH), a titan in the U.S. healthcare industry, is grappling with a formidable array of financial and operational challenges that are poised to exert immediate and substantial downward pressure on its Q3 2025 Earnings Per Share (EPS) estimates. A confluence of escalating high-acuity care costs, unfavorable
UnitedHealth Group (NYSE: UNH), a dominant force in the U.S. healthcare landscape, is currently embroiled in an unprecedented storm of regulatory and legal scrutiny. Federal Justice Department probes targeting its expansive vertical integration and Medicare Advantage billing practices are intensifying, while the company continues to reel from the catastrophic
